Lymphoma

ISCT 2021 highlights: therapeutic deception, global regulation & CAR-T 4:33
ISCT 2021 highlights: therapeutic deception, global regulation & CAR-T
Aaron Levine • 28 May 2021
Challenges of CAR T-cell therapy for AML: is CD38 the answer? 6:10
Challenges of CAR T-cell therapy for AML: is CD38 the answer?
Lei Yu • 3 Jun 2021
Horizon scanning in anti-CD19 CAR T-cell therapy 3:07
Horizon scanning in anti-CD19 CAR T-cell therapy
Marco Alessandrini • 20 May 2021
Improving education in cell therapy 1:33
Improving education in cell therapy
Emanuele Ostuni • 12 Apr 2021
Targetting cancer with allogeneic NK cell therapies 3:05
Targetting cancer with allogeneic NK cell therapies
James Trager • 10 Mar 2021
CAR-NKs for B cell malignancies 2:09
CAR-NKs for B cell malignancies
James Trager • 10 Mar 2021
CAR-T in DLBCL: 4-year follow-up data from ZUMA-1 2:13
CAR-T in DLBCL: 4-year follow-up data from ZUMA-1
Anna Sureda • 9 Feb 2021
Novel strategies to optimize CAR T-cell therapy 4:31
Novel strategies to optimize CAR T-cell therapy
Arnon Nagler • 1 Feb 2021
Infection prevention in patients receiving CAR T-cells 3:19
Infection prevention in patients receiving CAR T-cells
Joshua Hill • 10 Feb 2021
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies 3:30
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies
Jordan Gauthier • 28 Jan 2021
Infectious complications after CAR T-cell therapy 2:02
Infectious complications after CAR T-cell therapy
Joshua Hill • 10 Feb 2021
CAR-T in myeloma: key players in the therapeutic landscape 4:32
CAR-T in myeloma: key players in the therapeutic landscape
Mohamad Mohty • 26 Jan 2021
The impact of patient education on health outcomes for CAR T-cell therapy 3:15
The impact of patient education on health outcomes for CAR T-cell therapy
Lorna Warwick • 8 Feb 2021
The effect of COVID-19 on the experience of lymphoma patients undergoing CAR-T therapy 3:33
The effect of COVID-19 on the experience of lymphoma patients undergoing CAR-T therapy
Lorna Warwick • 8 Feb 2021
Update on ARI-0001 for patients with CD19+ R/R malignancies 2:47
Update on ARI-0001 for patients with CD19+ R/R malignancies
Manel Juan Otero • 25 Jan 2021
CAR-T vs. BiTEs in B-cell malignancies 6:09
CAR-T vs. BiTEs in B-cell malignancies
Marion Subklewe • 11 Feb 2021
The content of VJRegenMed is intended for healthcare professionals